Iftikhar N. Hussain
Expertise in
2
conditions

Dr. Iftikhar N. Hussain

Allergy Asthma And Immunology Center PC
Tulsa, OK
Expertise in
2
conditions
Specialties:Allergy and Immunology | Pain Medicine
Accepting New Patients
Offers Telehealth
Expertise in
2
conditions
OverviewInsuranceLocationsClinical Research

Overview

Iftikhar Hussain is an Allergy and Immunologist and a Pain Medicine provider in Tulsa, Oklahoma. Dr. Hussain is highly rated in 2 conditions, according to our data. His top areas of expertise are Primary Immunodeficiency (PID), Asthma, Grass Allergy, Sinusitis, and Myringotomy. Dr. Hussain is currently accepting new patients.

His clinical research consists of co-authoring 17 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Allergy and Immunology
Pain Medicine
Licenses
Internal Medicine in MO
Languages Spoken
English
Urdu
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Medica
  •  Humana
  •  CommunityCare

Locations

ALLERGY ASTHMA AND IMMUNOLOGY CENTER PC
7307 S Yale Ave, Suite 200, Tulsa, OK 74136
918-392-4550

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase 1 Open-label, Multi-centre, Single-arm Trial to Evaluate the Safety and Pharmacokinetics (Including MUsT) of Twice Daily Topical Application of Delgocitinib Cream for 8 Weeks in Adults, Adolescents, and Children With Moderate to Severe Atopic Dermatitis
A Phase 1 Open-label, Multi-centre, Single-arm Trial to Evaluate the Safety and Pharmacokinetics (Including MUsT) of Twice Daily Topical Application of Delgocitinib Cream for 8 Weeks in Adults, Adolescents, and Children With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2025
Intervention Type: Drug
Study Drug: Delgocitinib Cream
Study Phase: Phase 1
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 1b/2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of CNP-201 in Subjects Ages 16-55 With Peanut Allergy
A Phase 1b/2a Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of CNP-201 in Subjects Ages 16-55 With Peanut Allergy
Enrollment Status: Terminated
Publish Date: December 20, 2023
Intervention Type: Drug
Study Drug: CNP-201
Study Phase: Phase 1
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naïve Subjects With Primary Immunodeficiency
A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naïve Subjects With Primary Immunodeficiency
Enrollment Status: Completed
Publish Date: September 29, 2023
Intervention Type: Biological
Study Phase: Phase 4
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CDX-0159 as Add-on Therapy in Patients With Chronic Spontaneous Urticaria
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: CDX-0159, Normal Saline
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral Immunodeficiency
A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG Compared to Gamunex-C in Subjects With Primary Humoral Immunodeficiency
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Biological
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Crossover Study to Evaluate the Efficacy and Safety of LY3454738 in Adults With Chronic Spontaneous Urticaria Inadequately Controlled With H1-Antihistamines
Enrollment Status: Terminated
Publish Date: March 11, 2022
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 2
View 12 Less Clinical Trials

17 Total Publications

Public's Mental Health Monitoring via Sentimental Analysis of Financial Text Using Machine Learning Techniques.
Public's Mental Health Monitoring via Sentimental Analysis of Financial Text Using Machine Learning Techniques.
Journal: International journal of environmental research and public health
Published: June 18, 2022
Similar Doctors
Expertise in
17
conditions
Dr. Lynn A. Wiens
Allergy and Immunology
Expertise in
17
conditions
Dr. Lynn A. Wiens
Allergy and Immunology

Warren Clinic Inc

6600 S Yale Ave, Suite 1400, 
Tulsa, OK 
 (0.7 mi)
918-488-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lynn Wiens is an Allergy and Immunologist in Tulsa, Oklahoma. Dr. Wiens is highly rated in 17 conditions, according to our data. His top areas of expertise are Sinusitis, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Eosinophilic Pneumonia, and Simple Pulmonary Eosinophilia. Dr. Wiens is currently accepting new patients.

Expertise in
6
conditions
Dr. Frank J. Hackl
Pain Medicine | Anesthesiology
Expertise in
6
conditions
Dr. Frank J. Hackl
Pain Medicine | Anesthesiology

Access Pain Solutions

4716 S Urbana St, 
Broken Arrow, OK 
 (4.3 mi)
918-710-4112
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Frank Hackl is a Pain Medicine specialist and an Anesthesiologist in Broken Arrow, Oklahoma. Dr. Hackl is highly rated in 6 conditions, according to our data. His top areas of expertise are Chronic Pain, Cervical Spondylosis, Caudal Regression Syndrome, and Spondylocarpotarsal Synostosis Syndrome. Dr. Hackl is currently accepting new patients.

Expertise in
9
conditions
Dr. Jane T. Purser
Allergy and Immunology
Expertise in
9
conditions
Dr. Jane T. Purser
Allergy and Immunology

Allergy Clinic Of Tulsa Inc

9311 S Mingo Rd, 
Tulsa, OK 
 (3.6 mi)
918-307-1613
Languages Spoken:
English, Arabic, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jane Purser is an Allergy and Immunologist in Tulsa, Oklahoma. Dr. Purser is highly rated in 9 conditions, according to our data. Her top areas of expertise are Grass Allergy, Sinusitis, Allergic Rhinitis, and Primary Immunodeficiency (PID). Dr. Purser is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile